• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by 908 Devices Inc.

    3/7/25 9:15:51 AM ET
    $MASS
    Industrial Machinery/Components
    Industrials
    Get the next $MASS alert in real time by email
    S-8 1 tm258486d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 7, 2025

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    908 DEVICES INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware   45-4524096

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    645 Summer Street

    Boston, MA 02210
    (857) 254-1500

    (Address of Principal Executive Offices)

     

    908 Devices Inc. 2020 Stock Option and Incentive Plan

    (Full Title of the Plans)

     

    Kevin J. Knopp

    Chief Executive Officer

    645 Summer Street

    Boston, MA 02210

    (857) 254-1500

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Mark J. Macenka
    Michael J. Minahan
    Goodwin Procter LLP
    100 Northern Ave.
    Boston, MA 02210
    (617) 570-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

                 
    Large accelerated filer   ¨   Accelerated filer   ¨
           
    Non-accelerated filer   x   Smaller reporting company   x  
           
            Emerging growth company   x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 registers an additional 1,403,940 shares of the Registrant’s common stock, $0.001 par value per share (the “Common Stock”), to be issued under the Registrant’s 2020 Stock Option and Incentive Plan (the “2020 Plan”). The number of shares of Common Stock reserved and available for issuance under the 2020 Plan is subject to an automatic annual increase on each January 1, beginning in 2022, by an amount equal to the lesser of: (i) four percent (4%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31st, or (ii) such number of shares of Common Stock as determined by the Administrator (as defined in the 2020 Plan). Shares available for issuance under the 2020 Plan were previously registered on Form S-8 filed with the Securities and Exchange Commission on December 28, 2020 (Registration No. 333-251755), Form S-8 filed with the Securities and Exchange Commission on March 11, 2022 (Registration No. 333-263485), Form S-8 filed with the Securities and Exchange Commission on March 15, 2023 (Registration No. 333-270574), and Form S-8 filed with the Securities and Exchange Commission on March 8, 2024 (Registration No. 333-277800) (collectively, the “Registration Statement”). The information contained in the Registration Statement related to the 2020 Plan is hereby incorporated by reference pursuant to General Instruction E.

     

     

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    See the Exhibit Index below for a list of exhibits filed as part of this registration statement on Form S-8, which Exhibit Index is incorporated herein by reference.

     

    EXHIBIT INDEX

     

    Exhibit
    No.
     

    Description

       
    4.1   Sixth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.3 to the Registrant’s Registration Statement on Form S-1 (File No. 333-250954) filed with the SEC on November 25, 2020).
         
    4.2   Amended and Restated By-laws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.5 to the Registrant’s Registration Statement on Form S-1 (File No. 333-250954) filed with the SEC on December 14, 2020).
         
    5.1*   Opinion of Goodwin Procter LLP.
         
    23.1*   Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.
         
    23.2*   Consent of Goodwin Procter LLP (included in Exhibit 5.1).
       
    24.1*   Power of Attorney (included on signature page to this registration statement).
       
    99.1   2020 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-250954) filed with the SEC on December 14, 2020).
         
    107.1*   Filing Fee Table.

     

     

    *      Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, State of Massachusetts, on the 7th day of March, 2025.

     

      908 DEVICES INC.
         
      By:   /s/ Kevin J. Knopp, Ph.D.
        Kevin J. Knopp, Ph.D.
        Chief Executive Officer and Director

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints Kevin J. Knopp, Ph.D., who may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.

     

    Name   Title   Date
             

    /s/ Kevin J. Knopp, Ph.D.

    Kevin J. Knopp, Ph.D.

     

    Chief Executive Officer and Director

    (Principal Executive Officer)

      March 7, 2025
             

    /s/ Joseph H. Griffith IV

    Joseph H. Griffith IV

     

    Chief Financial Officer (Principal

    Financial and Accounting Officer)

      March 7, 2025
             

    /s/ Keith L. Crandell

    Keith L. Crandell

      Director   March 7, 2025
             

    /s/ Marcia Eisenberg, Ph.D.

    Marcia Eisenberg, Ph.D.

      Director   March 7, 2025
             

    /s/ Fenel M. Eloi

    Fenel M. Eloi

      Director   March 7, 2025
             

    /s/ Jeffrey P. George

      Director   March 7, 2025
    Jeffrey P. George        
             

    /s/ Tony J. Hunt

     

    Director

     

    March 7, 2025

    Tony J. Hunt        

     

    /s/ E. Kevin Hrusovksy

    E. Kevin Hrusovksy

      Director   March 7, 2025
             

    /s/ Mark Spoto

    Mark Spoto

      Director   March 7, 2025

     

    /s/ Michele M. Leonhart

    Michele M. Leonhart

      Director   March 7, 2025

     

     

     

     

    Get the next $MASS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MASS

    DatePrice TargetRatingAnalyst
    11/13/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    2/7/2023$14.00Overweight
    Stephens
    3/8/2022$40.00 → $30.00Outperform
    SVB Leerink
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $MASS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 908 Devices Equips rescEU Disaster Preparedness Reserve with Advanced Chemical Detection

      The company's handheld devices are incorporated in strategic CBRN stockpiles 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announced that its devices for rapid chemical detection at the point of need are being included in strategic stockpiles within Europe as part of rescEU, an EU-funded project that is establishing a reserve of disaster response capabilities. These reserves include stockpiles of chemical, biological, radiation and nuclear (CBRN) capabilities for detection, sampling, identification and monitoring due to unintentional disasters or intentional attacks. Over the past six months, the Company has shipped 108 devices to Europ

      4/30/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Receives $2M Order from the Texas Department of Public Safety for Drug Detection and Mitigation

      Multiple handheld MX908 devices will be deployed to detect, identify and mitigate illicit drugs like fentanyl, protecting communities amid the opioid crisis 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces a $2M order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry device. This investment in advanced tools for drug detection builds on an initial order placed last year for several MX908 devices, and is funded through the Community Oriented Policing Services (COPS) grant, a federally funded, state-administered program. The MX908 provides first responders with fast, actionable information when dea

      4/22/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Announces Preliminary First Quarter 2025 Financial Results

      At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re

      4/15/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • 908 Devices downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously

      11/13/24 8:05:47 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Stephens initiated coverage on 908 Devices with a new price target

      Stephens initiated coverage of 908 Devices with a rating of Overweight and set a new price target of $14.00

      2/7/23 6:37:28 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SVB Leerink reiterated coverage on 908 Devices with a new price target

      SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $30.00 from $40.00 previously

      3/8/22 4:31:59 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Leadership Updates

    Live Leadership Updates

    See more
    • 908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini

      6/25/24 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

      908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as

      3/2/22 4:30:00 PM ET
      $MASS
      $RGEN
      Industrial Machinery/Components
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 908 Devices Expands Scientific Advisory Board, Creates Dedicated Proteomics Panel

      Company appoints six new members to SAB to maximize the company's impact in the proteomics domain 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Prof. Ileana Cristea, Prof. Jennifer E. Van Eyk, Prof. Anne-Claude Gingras, Prof. Jesper Olsen, Prof. Renã Robinson, and Prof. John Yates. The new SAB members join the board's co-chairs, Christopher D. Brown, CTO 908 Devices; and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill, and existing members Prof. Jarrod

      8/2/21 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by 908 Devices Inc.

      DEFA14A - 908 Devices Inc. (0001555279) (Filer)

      4/28/25 9:03:24 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form DEF 14A filed by 908 Devices Inc.

      DEF 14A - 908 Devices Inc. (0001555279) (Filer)

      4/28/25 9:00:24 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form SCHEDULE 13G filed by 908 Devices Inc.

      SCHEDULE 13G - 908 Devices Inc. (0001555279) (Subject)

      4/7/25 4:18:42 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Knopp Kevin J. bought $64,200 worth of shares (10,000 units at $6.42), increasing direct ownership by 2% to 508,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/13/24 4:42:46 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Knopp Kevin J. bought $57,700 worth of shares (10,000 units at $5.77), increasing direct ownership by 2% to 498,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/10/24 6:36:05 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Knopp Kevin J. bought $58,300 worth of shares (10,000 units at $5.83), increasing direct ownership by 2% to 488,981 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/9/24 4:34:35 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 5:11:18 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 4:25:10 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      7/8/24 4:32:41 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Awm Investment Company, Inc. claimed ownership of 5,199,924 shares (SEC Form 3)

      3 - 908 Devices Inc. (0001555279) (Issuer)

      3/14/25 4:27:06 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by President and CEO Knopp Kevin J.

      4 - 908 Devices Inc. (0001555279) (Issuer)

      3/5/25 4:43:30 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Chief Financial Officer Griffith Joseph H. Iv

      4 - 908 Devices Inc. (0001555279) (Issuer)

      3/5/25 4:43:08 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    Financials

    Live finance-specific insights

    See more
    • 908 Devices Announces Preliminary First Quarter 2025 Financial Results

      At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re

      4/15/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results

      Divested desktop portfolio to Repligen for $70 million, including the MAVEN, MAVERICK, REBEL and ZipChip products Fourth quarter 2024 revenue increases 31% and full year 2024 revenue increases 19% compared to prior year Initiates revenue outlook for 2025 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety crises through the divestiture of its bioprocessing desktop assets to

      3/4/25 7:45:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

      WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen's differentiated PAT portfolio that provides its bioph

      3/4/25 7:30:00 AM ET
      $MASS
      $RGEN
      Industrial Machinery/Components
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care